James has made over 2 trades of the Ligand Pharmaceuticals stock since 2018, according to the Form 4 filled with the SEC. Most recently James exercised 5,000 units of LGND stock worth $90,850 on 2 April 2018.
The largest trade James's ever made was exercising 5,000 units of Ligand Pharmaceuticals stock on 2 April 2018 worth over $90,850. On average, James trades about 833 units every 6 days since 2004. As of 2 April 2018 James still owns at least 8,800 units of Ligand Pharmaceuticals stock.
You can see the complete history of James Litalien stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO, CA, 92121.
Over the last 21 years, insiders at Ligand Pharmaceuticals have traded over $205,340,014 worth of Ligand Pharmaceuticals stock and bought 2,116,600 units worth $27,601,439 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... e Partners L P/Ilbiotechnolog.... On average, Ligand Pharmaceuticals executives and independent directors trade stock every 22 days with the average trade being worth of $2,239,733. The most recent stock trade was executed by Octavio Espinoza on 28 August 2024, trading 753 units of LGND stock currently worth $50,090.
ligand, a pharmaceutical company, is assembling a large and diverse portfolio of current and near-term commercial revenue generating assets to assist the long-term financial growth of the company. we operate this business on a lean cost structure that allows us to maximize cash flow and ultimately deliver a meaningful return for our shareholders.
Ligand Pharmaceuticals executives and other stock owners filed with the SEC include: